FDA approves use of electronic chips in medications

by Bob Yirka report
Image: Proteus Digital Health

(Medical Xpress) -- The Food and Drug Administration in the United States has approved a request by Proteus Digital Health to allow for the inclusion of tiny digestible microchips into medicines to assist health care workers in monitoring intake of medicines by patients. Previously, the FDA had allowed such microchips only in placebo products. Proteus, the maker of the chips, plans to market them to drug manufactures who can then imbed them in individual pills that allow for electronic reporting to doctors letting them know if and when patients take their medicines.

The microchip, which is described as about the size of a grain of sand, is made of copper, and silicon, reacts with stomach juices when swallowed along with a pill. Upon reaction, it sends a signal to a patch the patient has applied to their skin where it is relayed to a smartphone. The then relays the information to the doctor’s office, allowing physicians to track how well a patient adheres to instructions on when and how often they are to take their meds. Proteus insists the aim is not to prod doctors and nurses into becoming nagging nannies, but to provide information that allows doctors to modify the types of medications they prescribe and the schedules to which the patients are asked to follow. Once the has done its job, it dissolves and passes out of the body along with other digested food.

The new technology is being pushed forward by recent reports that have found that just half of all patients take their medicines the way they are supposed to, which of course can reduce their effectiveness. Proteus believes some patients can benefit more than others from the microchips, such as those that take medicines to ward off tuberculosis, diabetics and elderly patients who have difficulty remembering to take their pills or if they’ve already taken them. Making things even more difficult, some have a whole list of with different schedules for each. The next logical step would of course be to allow the patient access to the data or to have it routed to a device set near where they keep their medicine, which would both alert them when it’s time to take their meds and to let them know if they can’t remember if they took them or not.

Some suggest this move by the FDA is the first of many likely to come over the next few years, as other technology is waiting in the wings. Coming soon may be swallowed or implanted devices that dose us automatically, sensors that report on other bodily activities, or devices that swim around in our bloodstream monitoring conditions and cleaning out plaque deposits.

More information: proteusdigitalhealth.com/

Related Stories

Chip-in-a-pill may be approved in 2012

Nov 10, 2010

(PhysOrg.com) -- Giant Swiss pharmaceutical company Novartis AG, based in Basel, is developing a pill containing an embedded microchip, which it hopes to submit for regulatory approval in Europe within 18 ...

Wireless medical monitors set to transform patient care

Mar 23, 2012

It's hard to find a better example of how technology is revolutionizing patient care than the tiny edible sensor Proteus Biomedical of Redwood City, Calif., plans to begin selling this fall in the United Kingdom.

Recommended for you

Determine patient preferences by means of conjoint analysis

17 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
1 / 5 (1) Aug 01, 2012
Do we really need to be monitored externally and internally?
IronhorseA
not rated yet Aug 01, 2012
Do we really need to be monitored externally and internally?

That's a question only your proctologist can answer. ;P
DarkHorse66
not rated yet Aug 06, 2012
Big Brother is watching You ;]

This is definitely getting closer to George Orwell's dystopia, '1984'

Cheers DH66